Aurinia Pharmaceuticals Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $79.4 million, 95% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
322
|
84
|
83
|
78
|
77
|
73
|
70
|
62
|
60
|
| Product |
307
+20.3%
share 95.3%
|
79
+12.4%
share 94.9%
|
79
+19.3%
share 95.4%
|
74
+22.7%
share 94.7%
|
74
+28.8%
share 96.2%
|
71
share 96.1%
|
67
share 95.1%
|
60
share 96.0%
|
58
share 96.2%
|
| License Collaboration And Royalty Revenue |
15
+37.3%
share 4.7%
|
4
+50.7%
share 5.1%
|
4
+10.9%
share 4.6%
|
4
+66.1%
share 5.3%
|
3
+28.7%
share 3.8%
|
3
share 3.9%
|
3
share 4.9%
|
2
share 4.0%
|
2
share 3.8%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AUPH (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Edmonton, Alberta, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1600620
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.